U.S. License Holder:
Celltrion
Date of License:
aBLA submitted to FDA June-2023
Last Update:
July-08-2024
FDA-Approved Indications
CT-P43 (ustekinumab) is not FDA-approved. An aBLA has been submitted to the FDA.
Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In South Korea
Steqeyma (Celltrion) (June-2024)